![]() |
|
|
Vol. 30, Issue 12, 1378-1384, December 2002
Department of Chemistry, Syracuse University, Syracuse, New York
(J.C.D., J.G.); and Department of Pediatrics, Upstate Medical
University, State University of New York, Syracuse, New York (A.-K.S.)
The reactions of cisplatin
[cis-diamminedichloroplatinum(II), CDDP] with
glutathione (GSH) and drug thiols were investigated at 37°C in 100 mM
Tris-NO3, pH ~7.4, using a clinically relevant concentration of CDDP (33 µM), a large excess of GSH (16.5 mM), and
[NaCl] of 4.62 mM. The conditions were designed to mimic passage of
CDDP through the cytosol. The reactions were studied by UV-absorption spectroscopy, high-pressure liquid chromatography (HPLC), and atomic
absorption spectroscopy. The initial rates, detected by UV
absorbance, confirmed that the reactions are first order in [CDDP].
The HPLC peak corresponding to CDDP was analyzed for platinum content
by atomic absorption spectroscopy, which decreased exponentially with
time, confirming that the reactions are first order in [CDDP] and
allowing determination of the pseudo first order rate constants (k1). For reaction of the dichloro form of
CDDP with GSH, the k1 value was ~2.2 × 10
4 s
1 (t1/2
of ~53 min), giving the second order rate constant value (k2) of ~1.3 × 10
2
M
1 s
1. Reaction of a mixture of the aquated
forms of CDDP with GSH gave a lower k1 value
(~0.9 × 10
4 s
1). Reaction of CDDP
with sodium 2-mercaptoethanesulfonate (mesna) gave a
k1 value of ~1.8 × 10
4
s
1 (t1/2 of ~65 min and
k2 of ~1.1 × 10
2
M
1 s
1). Reaction of CDDP with
S-2-(3-aminopropylamino)ethanethiol (WR-1065) gave a
k1 value of ~12.0 × 10
4 s
1 (t1/2 of
~10 min and k2 of ~7.3 × 10
2 M
1 s
1). The relatively
slow reaction rate of CDDP with GSH is consistent with the efficient
DNA platination by CDDP in the presence of millimolar concentration of
GSH in the cytosol.
This article has been cited by other articles:
![]() |
N. Ragunathan, J. Dairou, B. Pluvinage, M. Martins, E. Petit, N. Janel, J.-M. Dupret, and F. Rodrigues-Lima Identification of the Xenobiotic-Metabolizing Enzyme Arylamine N-Acetyltransferase 1 as a New Target of Cisplatin in Breast Cancer Cells: Molecular and Cellular Mechanisms of Inhibition Mol. Pharmacol., June 1, 2008; 73(6): 1761 - 1768. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Videhult, G. Laurell, I. Wallin, and H. Ehrsson Kinetics of Cisplatin and its monohydrated complex with sulfur-containing compounds designed for local otoprotective administration. Experimental Biology and Medicine, November 1, 2006; 231(10): 1638 - 1645. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. B. Hasinoff, X. Wu, O. V. Krokhin, W. Ens, K. G. Standing, J. L. Nitiss, T. Sivaram, A. Giorgianni, S. Yang, Y. Jiang, et al. Biochemical and Proteomics Approaches to Characterize Topoisomerase II{alpha} Cysteines and DNA as Targets Responsible for Cisplatin-Induced Inhibition of Topoisomerase II{alpha} Mol. Pharmacol., March 1, 2005; 67(3): 937 - 947. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Hagrman, J. Goodisman, and A.-K. Souid Kinetic Study on the Reactions of Platinum Drugs with Glutathione J. Pharmacol. Exp. Ther., February 1, 2004; 308(2): 658 - 666. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Hagrman, J. Goodisman, J. C. Dabrowiak, and A.-K. Souid KINETIC STUDY ON THE REACTION OF CISPLATIN WITH METALLOTHIONEIN Drug Metab. Dispos., July 1, 2003; 31(7): 916 - 923. [Abstract] [Full Text] [PDF] |
||||